Brensocatib is a small molecule commercialized by Insmed, with a leading Phase III program in Bronchiectasis. According to Globaldata, it is involved in 22 clinical trials, of which 17 were completed, 3 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Brensocatibs valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Brensocatib is expected to reach an annual total of $597 mn by 2034 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Brensocatib Overview
Brensocatib (INS-1007, AZD-7986) is under development for the treatment of neutrophil mediated diseases including non-cystic fibrosis bronchiectasis, cystic fibrosis, chronic obstructive pulmonary fibrosis (COPD), coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hidradenitis suppurativa and chronic rhinosinusitis without nasal polyps. The drug candidate is administered through oral route. It acts by targeting dipeptidyl peptidase 1 (DPP1).
It was also under development for granulomatosis with polyangiitis.
Insmed Overview
Insmed is a biopharmaceutical company that focuses on developing novel therapeutics for rare diseases. Its marketed product, Arikayce (liposomal amikacin for inhalation) is indicated for mycobacterium avium complex (MAC) lung infection and NTM lung infections caused by MAC in adult patients. The company uses its proprietary, liposomal technology to develop its novel drug candidates. Its pipeline products include brensocatib for non-cystic fibrosis (non-CF) bronchiectasis; TPIP, an inhaled formulation of a treprostinil prodrug for pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis, and PAH associated with interstitial lung diseases. The company operates in the US, the UK, the Netherlands, Ireland, Germany, Italy, France and Japan through its subsidiaries. Insmed is headquartered in Bridgewater, New Jersey, the US.
The company reported revenues of (US Dollars) US$305.2 million for the fiscal year ended December 2023 (FY2023), an increase of 24.4% over FY2022. The operating loss of the company was US$709.6 million in FY2023, compared to an operating loss of US$457.3 million in FY2022. The net loss of the company was US$749.6 million in FY2023, compared to a net loss of US$481.5 million in FY2022.
The company reported revenues of US$75.5 million for the first quarter ended March 2024, a decrease of 9.8% over the previous quarter.
For a complete picture of Brensocatibs valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
